New hope for young brain cancer patients: enzyme therapy targets tumors

NCT ID NCT07389278

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a drug called ADI-PEG 20, which breaks down an amino acid that some brain tumors need to grow. It is given alongside standard radiation and chemotherapy to children, adolescents, and young adults with newly diagnosed high-grade glioma. The goal is to see if this combination is safe and helps keep the cancer from progressing for longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ADI-PEG 20 (a modified enzyme that breaks down arginine, a nutrient some cancers need to grow)
What this could lead to
If it works, this could point toward a more effective treatment for children and young adults with high-grade glioma, potentially slowing tumor growth.
What could go wrong
This is an early phase 1/2 trial with only 97 participants, so results may not apply to everyone. The added drug may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE HEMISPHERIC GLIOMA, H3G34 MUTANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of California, San Francisco

    San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.